Victoza is an anti-diabetic drug owned by Novo Nordisk Inc. This medication contains liraglutide recombinant as its active ingredient and was first authorized for market use on January 25, 2010. Victoza, which is available in a subcutaneous solution form, holds a total of 14 patents. Among these patents, 5 have already expired.
The generic version of Victoza is expected to be available after July 9, 2037. This estimated date is primarily based on the expiration date of a key patent, US9968659, titled 'Liraglutide in cardiovascular conditions', set to expire on January 9, 2037. Despite several patents have already expired, the remaining patents prevent the release of a generic version until then.
Victoza is used to reduce the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease. Its effectiveness is attributed to its active ingredient, Liraglutide, which aids in improving glycemic control in adults with type 2 diabetes.
Victoza holds a total of 14 patents, of which 5 have already expired. Its remaining patents continue to protect it from generic competition until July 2037. This includes the influential patent 'Liraglutide in cardiovascular conditions' (US9968659), which expires in January 2037. More information on these patents can be found below in the patent details: